Haemonetics Corporation (FRA:HAZ)

Haemonetics Statistics

Total Valuation

Haemonetics has a market cap or net worth of EUR 2.41 billion. The enterprise value is 3.14 billion.

Market Cap	2.41B
Enterprise Value	3.14B

Important Dates

The last earnings date was Thursday, February 5, 2026.

Earnings Date	Feb 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.47M
Shares Outstanding	n/a
Shares Change (YoY)	-6.04%
Shares Change (QoQ)	-1.42%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	42.76M

Valuation Ratios

The trailing PE ratio is 16.19 and the forward PE ratio is 11.68.

PE Ratio	16.19
Forward PE	11.68
PS Ratio	2.15
PB Ratio	3.12
P/TBV Ratio	n/a
P/FCF Ratio	9.22
P/OCF Ratio	8.38
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.15, with an EV/FCF ratio of 12.01.

EV / Earnings	21.09
EV / Sales	2.81
EV / EBITDA	10.15
EV / EBIT	14.31
EV / FCF	12.01

Financial Position

The company has a current ratio of 1.75, with a Debt / Equity ratio of 1.34.

Current Ratio	1.75
Quick Ratio	1.04
Debt / Equity	1.34
Debt / EBITDA	3.36
Debt / FCF	3.98
Interest Coverage	5.32

Financial Efficiency

Return on equity (ROE) is 19.30% and return on invested capital (ROIC) is 11.27%.

Return on Equity (ROE)	19.30%
Return on Assets (ROA)	6.45%
Return on Invested Capital (ROIC)	11.27%
Return on Capital Employed (ROCE)	13.27%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	370,669
Profits Per Employee	49,329
Employee Count	3,023
Asset Turnover	0.52
Inventory Turnover	1.54

Taxes

In the past 12 months, Haemonetics has paid 43.97 million in taxes.

Income Tax	43.97M
Effective Tax Rate	22.77%

Stock Price Statistics

The stock price has decreased by -15.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.70%
50-Day Moving Average	60.71
200-Day Moving Average	55.94
Relative Strength Index (RSI)	42.87
Average Volume (20 Days)	1

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.83

Income Statement

In the last 12 months, Haemonetics had revenue of EUR 1.12 billion and earned 149.12 million in profits. Earnings per share was 3.10.

Revenue	1.12B
Gross Profit	674.71M
Operating Income	220.15M
Pretax Income	193.09M
Net Income	149.12M
EBITDA	310.17M
EBIT	220.15M
Earnings Per Share (EPS)	3.10

Balance Sheet

The company has 309.02 million in cash and 1.04 billion in debt, with a net cash position of -732.24 million.

Cash & Cash Equivalents	309.02M
Total Debt	1.04B
Net Cash	-732.24M
Net Cash Per Share	n/a
Equity (Book Value)	774.73M
Book Value Per Share	16.54
Working Capital	343.24M

Cash Flow

In the last 12 months, operating cash flow was 288.01 million and capital expenditures -26.15 million, giving a free cash flow of 261.86 million.

Operating Cash Flow	288.01M
Capital Expenditures	-26.15M
Free Cash Flow	261.86M
FCF Per Share	n/a

Margins

Gross margin is 60.21%, with operating and profit margins of 19.65% and 13.31%.

Gross Margin	60.21%
Operating Margin	19.65%
Pretax Margin	17.23%
Profit Margin	13.31%
EBITDA Margin	27.68%
EBIT Margin	19.65%
FCF Margin	23.37%

Dividends & Yields

Haemonetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.04%
Shareholder Yield	6.04%
Earnings Yield	6.18%
FCF Yield	10.85%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 3, 2012. It was a forward split with a ratio of 2.

Last Split Date	Dec 3, 2012
Split Type	Forward
Split Ratio	2

Scores

Haemonetics has an Altman Z-Score of 2.5 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.5
Piotroski F-Score	6